The Staghound

@thestaghound

Ya ever heard of IDO? It failed. No monotherapy efficacy? It’s gonna fail. Former analyst at a life sciences focused-fund, but now investing on my own.

Vrijeme pridruživanja: siječanj 2018.

Tweetovi

Blokirali ste korisnika/cu @thestaghound

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @thestaghound

  1. Prikvačeni tweet
    2. lis 2019.
    Odgovor korisnicima

    I'd pay to see beat down

    Poništi
  2. prije 4 sata

    hmmmm 🍊

    Poništi
  3. prije 8 sati
    Poništi
  4. prije 10 sati
    Poništi
  5. 4. velj

    Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro | Cell Research

    Poništi
  6. 4. velj
    Poništi
  7. 4. velj

    Gonna short fuck all of you

    Poništi
  8. 3. velj

    Has anyone done a lot of work in ? I have, but I still cannot get convinced that will be the most differentiated company in the space...

    Poništi
  9. 31. sij

    Gains from yesterday...

    Poništi
  10. proslijedio/la je Tweet
    30. sij

    1). This is at least the 4th person to comment that "Black Diamond" ( ) is "such a GOOD NAME" "Black Diamond" must be connoting differentiation of the BDTX-189 product in kinase space (exon 20; less toxic)

    Prikaži ovu nit
    Poništi
  11. proslijedio/la je Tweet
    30. sij
    Poništi
  12. proslijedio/la je Tweet
    30. sij

    Black Diamond Therapeutics IPO priced at $19, currently indicating $30 open.

    Poništi
  13. 30. sij

    Looks like is 23-25x oversubscribed c/o:

    Poništi
  14. 30. sij

    Anybody else want this smoke? didn’t want it

    Poništi
  15. 30. sij

    All I’m saying is, if -189 is the only WT-sparing EGFR TKI with activity towards exon 20... 💰💰💰

    Poništi
  16. 30. sij

    Anybody know when and begin normal trading today?

    Poništi
  17. 30. sij

    SO PUMPED FOR and TOMORROW

    Poništi
  18. proslijedio/la je Tweet
    30. sij

    Black Diamond Therapeutics prices . 10.58M shares at $19/share.

    Poništi
  19. 29. sij

    Anyway I'm loaded up on .

    Prikaži ovu nit
    Poništi
  20. 29. sij

    Also is an Fc fusion protein with point mutations, and this can lead to immunogenicity risk. Wonder how big of an issue that actually is in the clinic.

    Prikaži ovu nit
    Poništi
  21. 29. sij

    If shits the bed... bad news for . Both companies have very similar drugs going after ... but it's important to remember that even if doesn’t show promising data, still has a upper hand given it’s likely more safe and can be dosed higher than

    Prikaži ovu nit
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·